Skip to main content

Drug Interactions between Adbry and influenza virus vaccine, live

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

influenza virus vaccine, live tralokinumab

Applies to: influenza virus vaccine, live and Adbry (tralokinumab)

GENERALLY AVOID: The administration of live, attenuated viral or bacterial vaccines during therapy with the interleukin-13 antagonists tralokinumab or lebrikizumab may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. This interaction may also apply to oncolytic cancer immunotherapy agents, such as BCG, talimogene laherparepvec, and nadofaragene firadenovec. However, data evaluating the impact of these drugs on the safety and effectiveness of these vaccines or oncolytic cancer immunotherapy agents is not available.

MANAGEMENT: The manufacturers of tralokinumab and lebrikizumab recommend that the use of live, attenuated virus or bacterial vaccines be avoided during treatment with these drugs. Administration of all age-appropriate vaccines is recommended to be completed prior to initiation of either tralokinumab or lebrikizumab, and in accordance with current immunization guidelines. Until further information is available, concomitant use of oncolytic cancer immunotherapy agents such as BCG, talimogene laherparapvec, and nadofaragene firadenovec should also generally be avoided.

References (2)
  1. (2024) "Product Information. Ebglyss Pre-filled Pen (lebrikizumab)." Eli Lilly Canada Inc
  2. (2024) "Product Information. Ebglyss Prefilled Syringe (lebrikizumab)." Lilly, Eli and Company

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer